98289847MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:

  • MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
  • MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
  • MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
  • MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

 

 

Therapeutic Candidate

Indication

Discovery Optimization

Preclinical Development

Phase 1

Phase 2

Phase 3

MCT-125

PMSF

MCT-465

Cancer

MCT-475

Cancer

MCT-485

Cancer